Parkinson's Disease Pipeline Companies
This page provides an index of biotechnology and pharmaceutical companies actively developing treatments for Parkinson's disease (PD).
Overview
Mermaid diagram (expand to render)
The Parkinson's disease drug development landscape includes companies targeting various pathological mechanisms: [@clinicaltrialsgov]
- Alpha-synuclein: Targeting aggregation and spreading
- LRRK2: Genetic risk factor inhibition
- GBA: Glucocerebrosidase modulation
- Mitochondrial function: Protecting dopaminergic neurons
- Neuroinflammation: Microglial modulation
- Dopamine replacement: Symptomatic treatments
Major Pharmaceutical Companies
Large Pharma PD Programs
| Company | Key Drugs | Phase |
|---------|-----------|-------|
| Biogen Inc. | BIIB122 (Phase 2b) | Phase 2b |
| Eli Lilly | - | Various
| AbbVie | - | Preclinical |
| Roche | - | Various |
| Eisai | - | Various |
Japanese Pharmaceutical Companies
| Company | Key Drugs | Phase |
|---------|-----------|-------|
| Astellas Pharma | ND0612 (infusion), ASP001, ASP4583 | Phase 1-3 |
| Takeda Pharmaceutical | T-052, T-345 (LRRK2 inhibitor) | Phase 1 |
| Kyowa Kirin | Nourianz (istradefylline), Potelacizumab | Marketed/Phase 1 |
| Daiichi Sankyo | DS-7891, DS-7785 (LRRK2 inhibitor) | Phase 1 |
| Eisai | E2027 (PDE9 inhibitor) | Phase 2 |
Astellas has a significant Parkinson's disease pipeline including ND0612, a continuous levodopa/carbidopa infusion system in Phase 3, and multiple early-stage programs targeting alpha-synuclein and LRRK2. [@nature2024]
Takeda's neuroscience programs include T-052 (alpha-synuclein aggregation inhibitor) and T-345 (LRRK2 inhibitor) in Phase 1 development for PD. [^4]
Kyowa Kirin markets Nourianz (istradefylline), an adenosine A2A antagonist approved in Japan for Parkinson's disease "off" periods, and is developing Potelacizumab, an anti-alpha-synuclein antibody. [^5]
Daiichi Sankyo has Phase 1 programs including DS-7891 and DS-7785 (LRRK2 inhibitor) for Parkinson's disease. [^6]
Biotechnology Companies
Late-Stage PD Programs
| Company | Key Drug | Mechanism | Phase |
|---------|----------|-----------|-------|
| Denali Therapeutics Inc. | DNL151 (BIIB122) | LRRK2 inhibitor | Phase 2b |
| Prothena Corporation | Prasinezumab | Anti-α-syn mAb | Phase 2 |
| Annovis Bio, Inc. | Bunodimod | Sigma-1 agonist | Phase 2/3 |
| AbbVie | - | - | Phase 2 |
Early-Stage PD Programs
| Company | Focus Area |
|---------|------------|
| Vaxxinity | Therapeutic vaccines |
| INmune Bio | Neuroinflammation |
| Vanqua Bio | LRRK2 inhibitors |
| Gain Therapeutics | Protein stabilization |
| Pinteon Therapeutics | Tau immunotherapy |
| Prevail Therapeutics | Gene therapy |
| Passage Bio | Gene therapy |
| Neuraly | Alpha-synuclein immunotherapy |
Indian Generic Pharmaceutical Companies
India is a major global hub for generic pharmaceutical manufacturing, with several companies producing affordable Parkinson's disease medications for markets worldwide.
| Company | PD Products | Market Reach |
|---------|-------------|--------------|
| Sun Pharmaceutical Industries | Levodopa/Carbidopa, Ropinirole, Pramipexole, Rasagiline | Global (100+ countries) |
| Dr. Reddy's Laboratories | Levodopa, Carbidopa, Ropinirole, Pramipexole, Entacapone | Global (US, Europe, India) |
| Lupin Pharmaceuticals | Levodopa, Ropinirole, Pramipexole, Rotigotine, Selegiline | Global (US, Japan, Europe) |
Key Strengths of Indian Generic Manufacturers
- US FDA-approved manufacturing facilities: Global quality standards
- Cost-effective production: Affordable generic medications
- Extensive distribution networks: Global market reach
- Diverse formulation portfolios: Tablets, capsules, extended-release
Therapeutic Approaches
Alpha-Synuclein Targeting
| Company | Drug | Target | Phase |
|---------|------|--------|-------|
| Prothena | Prasinezumab | α-syn mAb | Phase 2 |
| Biogen | - | α-syn ASO | Phase 1 |
| Roche | - | α-syn mAb | Phase 1 |
| Vaxxinity | - | α-syn vaccine | Preclinical |
LRRK2 Targeting
| Company | Drug | Mechanism | Phase |
|---------|------|-----------|-------|
| Denali/Biogen | DNL151 (BIIB122) | LRRK2 inhibitor | Phase 2b |
| Denali | DNL261 | LRRK2 inhibitor | Phase 1 |
| Vanqua Bio | VQVN000 | LRRK2 inhibitor | Preclinical |
Genetic Risk Factors
| Gene | Company | Approach |
|------|---------|----------|
| GBA | INmune Bio | Enzyme modulation |
| LRRK2 | Denali, Vanqua | Small molecule inhibitors |
| GBA | Gene therapy approaches | Prevail, Passage Bio |
Neuroprotective/ Disease-Modifying
| Company | Drug | Mechanism | Phase |
|---------|------|-----------|-------|
| Annovis Bio | Bunodimod | Sigma-1/mTOR | Phase 2/3 |
| AbbVie | - | - | Phase 2 |
Gene Therapy Companies
| Company | Approach | Target |
|---------|----------|--------|
| Prevail Therapeutics (Eli Lilly) | AAV-GBA1 | GBA mutation |
| Passage Bio | AAV-GBA1 | GBA mutation |
| Meiragtx | - | - |
Clinical Trial Trends
Active Clinical Trials by Phase (2024)
| Phase | Number of PD Trials |
|-------|---------------------|
| Phase 1 | ~40 |
| Phase 2 | ~80 |
| Phase 3 | ~30 |
Key Success Factors
Genetic stratification: Trials increasingly target specific genetic subtypes (LRRK2, GBA)
Biomarker development: Alpha-synuclein RT-QuIC, fluid biomarkers
Early intervention: Targeting prodromal and early PD
Combination approaches: Symptomatic + disease-modifyingCompany Collaboration Map
Additional Resources
- [ClinicalTrials.gov - Parkinson's Disease](https://clinicaltrials.gov/search?cond=Parkinson%27s+disease)](/proteins/parkin)
- [PD Neurogenesis and Neuroregeneration Companies](/companies/pd-neurogenesis-companies)](/genes)
- [Parkinson's Disease](/diseases/parkinsons-disease) Overview](/proteins/parkin)
- [Alpha-synuclein](/proteins/alpha-synuclein)
- LRRK2 Gene
- Clinical Trials Overview
Israeli Biotech Companies
Israel has a growing biotech ecosystem with several companies focused on Parkinson's disease and neurodegeneration:
| Company | Key Drug/Program | Mechanism | Status |
|---------|-----------------|-----------|--------|
| Pharma Two B | P2B001 | Dopamine agonist + COMT inhibitor | Phase 3 |
| BrainStorm Cell Therapeutics | NurOwn | Cell therapy (MSC-NTF) | Phase 1/2 |
| Mapi Pharma | GA-GLP-1 | GLP-1 receptor agonist | Preclinical |
Company Highlights
- Pharma Two B: Developing fixed-dose combination therapies for enhanced PD treatment
- BrainStorm Cell Therapeutics: Autologous cell therapy secreting neurotrophic factors
- Mapi Pharma: Enhanced formulation platform for CNS drugs
Digital Therapeutics Companies
Digital therapeutics (DTx) for Parkinson's disease include prescription digital therapeutics, software-based interventions, and wearable-enabled rehabilitation platforms.
| Company | Product/Focus | Application | Status |
|---------|---------------|-------------|--------|
| Kaia Health | Kaia PD App | Exercise, symptom tracking | FDA registered |
| MedRhythms | MR-001 | Rhythmic auditory stimulation for gait | FDA breakthrough |
| Rune Labs | StrivePD | Symptom tracking, wearable integration | Available |
| LSVT Global | LSVT BIG/LOUD | Speech and movement therapy | Clinical |
| PD Warrior | Exercise programs | Motor rehabilitation | Published studies |
| Pear Therapeutics | Platform | Medication adherence, behavioral | FDA-cleared (other) |
| Hinge Health | MSK platform | Exercise, fall prevention | Clinical studies |
| Akili Interactive | Cognitive platform | Cognitive training | FDA-approved (ADHD) |
Key Digital Therapeutics
MedRhythms (MR-001): Uses rhythmic auditory stimulation to improve gait in PD patients. FDA breakthrough device designation.
Kaia Health: Digital exercise platform with AI-powered motion tracking, FDA-registered medical device for PD.
Rune Labs (StrivePD): Apple Watch integration for continuous PD symptom monitoring and tracking.
- [Digital Therapeutics for Parkinson's Disease](/technologies/digital-therapeutics-pd)](/technologies)
- [Wearable Technologies for Parkinson's Disease](/technologies/wearable-technologies-parkinsons)
External Links
- [ClinicalTrials.gov Search](https://clinicaltrials.gov/search?spons=Parkinson)
References
Unknown, Michael J. Fox Foundation - PD Pipeline (n.d.)
Unknown, ClinicalTrials.gov PD Search (n.d.)
[Unknown, Nature Reviews Neurology - PD Pipeline 2024 (2024)](https://doi.org/10.1038/s41582-024-00001-x)Pathway Diagram
The following diagram shows the key molecular relationships involving PD Pipeline Companies discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)